Patent ID: 7741306

Claim:
A method for increasing the sensitivity of a cell to radiotherapy comprising: administering a composition comprising a let-7 miRNA and a suitable pharmaceutical carrier to a cell of a patient, that binds to and inhibits the expression of an mRNA encoded by an oncogene containing a let-7 complementary site (LCS) selected from the group consisting of NRAS, KRAS, HRAS, MYC, MYCL1, MYCN, BCL2, BCL2L1, BCL2L2, TERT, VEGF, EGF, EGFR, ERBB3, GRB2, RAF1, ARAF, MAP2K2, MAPK1, MAPK3, MET, KIT, TP73L(AIX), CCND1, CDK4, MDM2, FES, FURIN, INSL3, CSFIR, MYBL2, MYB, PIK3CD, PIK3C2B, PIK3CG, PIK3R5, AKT1, HLIN-41, VDR, PXR, FOXA1, FOXA2, ASH1L, ARID1B, GR, GLI2, 14-3-3zeta, MO25, SMGI, FRAP1, PER2 and AKT3 in a cell of a patient, and subsequently administering radiation to said patient, wherein said let-7 miRNA is administered in an effective amount to sensitize the cell to said radiotherapy and wherein said let-7 miRNA is selected from the group consisting of let-7a1, let-7a2, let-7a3, let-7b, let-7c, let-7d, let-7f, let-7h, let-7i, and mir-98.